HOTH News and Press, Hoth Therapeutics Inc. From 03/03/21

Hoth Therapeutics Provides Update on Novel Peptide COVID-19 Therapeutic HT-002 Preclinical Studies Analysis supports that these optimized peptides could be effective against the emerging UK and South African SARS-CoV-2 strain variants PR Newswire NEW YORK , Mar...

Hoth Therapeutics ([[HOTH]] +0.9%) announces that it has completed recruitment of cohort 1 for its upcoming first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as eczema.The company hopes to report preliminary results from the study la...

Hoth Therapeutics Completes Site Recruitment for Cohort 1 of First in Human Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis PR Newswire NEW YORK , March 1, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company...

Hoth Therapeutics (HOTH) expands its licensing agreement from North Carolina State University to include the worldwide development and commercialization of treatments targeting mast cell derived cancers and anaphylaxis. The HT-KIT drug is designed to more specifically target th...

Hoth Therapeutics Expands License Agreement to Include Innovative Cancer and Anaphylactic Treatment PR Newswire NEW YORK , Feb. 26, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company , today announced it has exp...

Hoth Therapeutics Retains RedChip to Increase Investor Awareness PR Newswire NEW YORK , Feb. 25, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company , today announced it retained RedChip Companies, Inc. ("RedChip...

Hoth Therapeutics ([[HOTH]] +16.2%) has filed a provisional patent application with the United States Patent and Trademark Office for the use of one of its current portfolio therapeutics to treat and prevent Alzheimer's disease.The company has also secured an exclusive lic...

Hoth Therapeutics Expands Intellectual Property Portfolio with Novel Alzheimer's Treatment PR Newswire NEW YORK , Feb. 24, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has filed a p...

Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Development of HT-001 For Cancer Patients Hoth intends to pursue FDA Expedited Programs, such as Breakthrough Designation, pending generation of future clinical study data for HT-001...

Hoth Therapeutics (HOTH) intends to expand the development of the HT-003 active pharmaceutical ingredient ((API)) to pursue a new indication for the treatment of inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis.Hoth executed an option agreement with Is...